WO2020203196A1

WO2020203196A1 - Composition for improving athletic ability

Info

Publication number: WO2020203196A1
Application number: PCT/JP2020/011263
Authority: WO
Inventors: 寛人森田; 智恵狩野; 哲平中村
Original assignee: アサヒグループホールディングス株式会社
Priority date: 2019-03-29
Filing date: 2020-03-13
Publication date: 2020-10-08
Also published as: TW202103573A; JP7528056B2; AU2020254431A1; JPWO2020203196A1

Abstract

The present invention addresses the problem of providing a novel composition that can contribute to improvement of athletic ability. As a solution to the problem, provided is a composition that is for improving athletic ability and that contains linseed lignan as an active ingredient. The improvement of athletic ability includes at least one effect selected from improvement of physical strength, fatigue resistance, and reduction of feeling fatigued. Also, provided is a composition that is for growth of Bacteroides uniformis in the intestinal tract and that contains linseed lignan as an active ingredient. Linseed lignan is preferably administered in an amount of 0.01-200 mg/kg body weight per day, and is preferably administered for at least 7 days.

Description

Composition for improving athletic performance

The present invention relates to an orally ingestible composition for improving athletic performance and an orally ingestible composition for growing Bacteroides uniformis which can contribute to the improvement of athletic performance.

The seed of flax (scientific name: Linum usitatissimum), "flax (flaxseed)" is rich in a kind of polyphenol "lignan", and the lignan obtained from flax is generally called "flax lignan". ing. More specifically, amani lignans are a series of secoisolariciresinol diglycoside (SDG), its metabolites enterodiol and enterolactone, matairesinol, pinoresinol, isolaricilesinol, etc. It is a lignan compound. Patent Document 1 describes that the combined use of this amani lignan and xanthophyll may have an effect of improving peripheral blood circulation disorders. Further, Patent Document 2 describes that an anti-obesity effect can be promoted by using amanilignan in combination with mazindol, which is known as a central nervous system anti-obesity drug. Further, in Patent Document 3, amani lignan is described as an estrogen-like substance. Isoflavones are mentioned as a typical estrogen-like substance, and Patent Document 4 discloses that the mileage of a treadmill of a mouse ingesting 4', 7-dimethoxyisoflavone is increased. However, no literature has been confirmed that discloses the physical fitness improving effect of the linseed extract and the linseed lignan contained in the linseed extract. Non-Patent Document 1 suggests that SDGs in amani lignans may be efficiently converted to SECO (secoisolariciresinol) by Bacteroides unforus, which is known as an intestinal bacterium, in an in vitro system. There is. However, the document makes no mention of the proliferation of Bacteroides uniformis.

In addition, attention is focused on general health foods that can contribute to the maintenance and promotion of health, and in response to this trend, it is possible to display health functions for foods that meet certain standards and standards even in Japan. It has become. In addition, due to the recent health boom, there is a high demand for health foods that can contribute to improving athletic performance. Usually, when performing activities such as labor and exercise, it is necessary to have at least enough physical strength to withstand these activities. On the other hand, these activities cause fatigue to accumulate in the body and reduce the function of the body. It can be said that maintenance / improvement of physical strength and prevention / recovery of fatigue are indispensable for daily activities such as labor and exercise. Physical fitness for activities such as work and exercise includes physical abilities that are the basis of actions such as muscular strength, endurance, and flexibility. Against this background, compositions for enhancing endurance, preventing fatigue or recovering from fatigue, or for nourishing tonic have been developed, but further development of new health foods is required.

Japanese Unexamined Patent Publication No. 2008-239619 JP 2015-199687 Re-table 2014-050717 Special Table 2009-537582

An object of the present invention is to provide a novel composition that can contribute to the improvement of athletic performance.

The present inventors have obtained the finding that ingestion of Bacteroides uniformis has a continuous physical fitness improving effect and / or an anti-fatigue effect (International Publication No. 2019/069735 (PCT / JP2018 / 035295). (Refer to the international publication that was unpublished at the time of filing the basic application of this international application (Japanese Patent Application No. 2019-067,505)). Based on these findings, the present inventors consider that Bacteroides unformis, which is known as one of the bacteria constituting the intestinal flora, is one of the factors that bring about a physical fitness improving effect and / or an anti-fatigue effect. I thought it might be. Therefore, as a result of intensive studies, it was confirmed that the number of intestinal Bacteroides uniformis was unexpectedly increased and that athletic performance was improved in the human test group ingesting amanilignan. .. Then, as a result of such research, the present invention was completed.

That is, the present invention is configured as follows [1] to [7].
[1] A composition for improving athletic performance, which contains amani lignan as an active ingredient.
[2] The composition according to the above [1], wherein the improvement of athletic ability includes at least one action selected from improvement of physical strength, anti-fatigue, and reduction of fatigue.
[3] A composition for breeding Bacteroides uniformis in the intestinal tract, which contains amani lignan as an active ingredient.
[4] The composition according to any one of the above [1] to [3], which is for oral ingestion.
[5] The composition according to any one of [1] to [3] above, which is an additive for food and drink, a pharmaceutical composition, a feed composition, or an additive for feed.
[6] The composition according to any one of [1] to [5] above, wherein an amani lignan in an amount of 0.01 mg mg / kg body weight to 200 mg / kg body weight is administered per day.
[7] The composition according to any one of [1] to [6] above, which is administered for at least 7 days.

The present invention can provide a novel composition that contributes to the improvement of athletic performance.

It is a figure which shows the change in the number of Bacteroides uniformis in the intestinal tract of a subject before ingestion (0 week) and 8 weeks after ingestion of a test food. The statistical examination between the number of bacteria before ingestion and the number of bacteria 8 weeks after ingestion was performed by Wilcoxon signed-rank test. The subjects were subjected to exercise load using an exercise bike (registered trademark) before and 8 weeks after ingestion of the test food, and a VAS (Visual Analogue Scale) questionnaire was conducted regarding fatigue before, immediately after, and 30 minutes after the load. It is the figure which summarized the feeling of general fatigue after 30 minutes of our load. The significant difference test between the placebo group and the amanilignan intake group for general fatigue was performed by the student's t-test. In addition, a significant difference was examined by a paired t-test for comparison between before ingestion of amanilignan and 8 weeks after ingestion of amanilignan. It is the result of measuring the maximum oxygen uptake at the time of exercise load for the subject before ingestion of the test food and 9 weeks after ingestion. A significant difference was examined by a paired t-test for comparison between before ingestion of amanilignan and 9 weeks after ingestion of amanilignan.

<Composition for improving athletic performance>
The present invention relates to a composition having an athletic performance improving action, which comprises amani lignan. In the present invention, the "exercise ability improving action" refers to at least one action selected from "physical strength improving action", "fatigue reduction", "anti-fatigue", and "fatigue tolerance improving action". The amani lignan in the present invention means all the lignans obtained from amani. Amani lignans include lignans of various structures, but the major lignans are secoisolariciresinol diglycoside (SDG) and its metabolites enterodiol, enterolactone, matairesinol, pinoresinol, and isolarisilesi. A series of lignan compounds such as Noll. Amani lignans are contained in the amani extract, and the extract may be used in the present invention. The flaxseed extract can be obtained by concentrating the juice or extract obtained from flaxseed or flaxseed meal by a method such as pressing or solvent extraction. For extraction, a solvent such as water, methanol, ethanol, or isopropanol can be used. In addition, purification may be performed if necessary. In the present invention, a composition using amani lignan as an active ingredient can significantly improve athletic performance. Here, since the main component of amani lignan is SDG, the amount of "amani lignan" in the composition in the present specification can be defined as synonymous with the amount of secoisolariciresinol diglycoside (SDG) for convenience. However, this definition does not imply that the composition does not contain trace amounts of lignans other than the SDGs contained in amani lignans.

In the present invention, "physical strength" refers to the physical ability that is the basis of an action that enables activities such as labor and exercise, and in particular, makes it possible to endure activities such as labor and exercise, and continuously. It means the physical strength that makes it possible to do them. More preferably, "physical fitness" means one or more of whole body endurance and endurance during aerobic exercise that enables continuous aerobic exercise. "Whole body endurance" refers to the ability to move the body for a long time, which is also generally called stamina.

In the present invention, "improvement of physical fitness" means one or more of promoting improvement and recovery of physical fitness, and in particular, it is possible to endure activities such as labor and exercise and to continuously perform them. It means one or more of improving physical strength and promoting recovery of the physical strength, and more preferably, improving one or more of whole body endurance and endurance during aerobic exercise. Means one or more selected from the group consisting of doing and promoting the recovery of one or more of whole body endurance and endurance during aerobic exercise. The index of the endurance of the whole body and the endurance during aerobic exercise is not limited, but for example, the maximum oxygen uptake and the result of the spin cycle test can be used.

In the present invention, "fatigue" means that the function of the body deteriorates as a result of continuous activities such as labor and exercise.
In the present invention, "fatigue" is a sensation of being aware of the existence of fatigue, and in many cases, discomfort and decreased motivation for activity are recognized. General malaise, tiredness, and weakness seen in various illnesses are used almost synonymously with "fatigue."

In the present invention, "anti-fatigue" and "improving fatigue resistance" are synonymous and mean one or more of reducing fatigue, promoting recovery from fatigue, and preventing fatigue. , Preferably, reduce the deterioration of physical function resulting from continuous activities such as work and exercise, promote the recovery of the deterioration of physical function, or prevent the deterioration of physical function. This means that the physical function is less likely to deteriorate. Although not limited, "anti-fatigue" and "fatigue tolerance improving effect" can be evaluated by, for example, a VAS questionnaire, a spin cycle test, a maximum oxygen uptake, and the like.
In the present invention, "reducing the feeling of fatigue" means reducing the sensation of being aware of the existence of fatigue, discomfort and / or willingness to act as a result of continuous activities such as work and exercise. It means one or more of alleviating the decrease in discomfort, promoting recovery from the decrease in discomfort and / or motivation for activity, and preventing the decrease in discomfort and / or motivation for activity. Although not limited, the "fatigue reducing effect" can be evaluated by, for example, a VAS questionnaire.

The amount of amani lignan contained in the composition of the present invention may vary depending on the dosage form and form of the composition, but is 1% by mass or more, preferably 5% by mass or more, more preferably 5% by mass or more with respect to the composition. It can be 10% by mass or more. For example, when the composition of the present invention is molded in the form of a tablet having a total volume of 250 mg, the amount of amani lignan contained in one tablet is 2.5 mg or more, preferably 12.5 mg or more, more preferably 25 mg or more. be able to.

The subject (subject) to which the composition of the present invention is administered is a mammal (for example, human, primate (monkey, chimpanzee, etc.)) that requires one or more of the effects of improving physical strength, reducing fatigue, and anti-fatigue. ), Domestic animals (cattle, horses, pigs, sheep, etc.), pets (dogs, cats, etc.), experimental animals (mouses, rats, etc.)), birds, reptiles, etc., but mammals are preferable, and particularly preferable. Is a human.
Then, in the present invention, not only a subject having no exercise habit (for example, a human) but also a human having a certain exercise habit can bring about an effect of improving exercise ability. For example, the subject may be a human who exercises at least once a week and at least 5 METs for 30 minutes or more. It is possible to improve the athletic ability even for a subject having such an appropriate exercise habit. It can also improve fatigue tolerance during and / or after moderate to high intensity exercise such as walking, jogging, running, marathon, swimming, cycling, aerobics, tennis, soccer, skiing, and skating. Since the feeling of fatigue can be reduced, the accumulation of fatigue can also be suppressed. Note that METs (metabolic equivalent of task) is an index of exercise intensity, and 1 MET is equal to an oxygen uptake of 3.5 ml / body weight kg / min, which is an oxygen demand required for the body to function at rest.

The dose or intake of the composition of the present invention may vary depending on factors such as the age and body weight of the subject, the route of administration, the number of administrations / intakes, physical strength and the degree of fatigue, and any dose. Alternatively, the intake may be adopted. For example, when administered or ingested orally, the intake of amanilignan is 0.01 mg / kg body weight or more, preferably 0.1 mg / kg body weight or more, more preferably 1 mg / kg body weight or more, and also. An amount selected from 200 mg / kg body weight or less, preferably 50 mg / kg body weight or less, more preferably 10 mg / kg body weight or less, once or multiple times (for example, 2 to 5 times, preferably 2 to 3 times). It can be administered or ingested separately.

The composition of the present invention can be effective in a small amount and in a short period of time, but a higher effect tends to be obtained by administering or ingesting the composition over a long period of time. The composition of the present invention can be confirmed to have an effect of improving athletic performance by administration or ingestion for at least 7 days or more. For example, the composition of the present invention is used for 14 days or more and 1 month according to the above dosage. It is more preferable to continuously administer or ingest the drug over a period of 2 months or longer, 6 months or longer, 1 year or longer, or longer.

The composition of the present invention has an effect of improving athletic performance. Specifically, the composition of the present invention withstands and continues one or more of improving and recovering physical fitness, particularly labor and exercise, in a subject administered or ingested as compared to the case where it is not administered or ingested. One or more of improving the physical strength that makes it possible to do them, and promoting the recovery of the physical strength, more preferably the whole body endurance and the endurance during aerobic exercise. It can bring about one or more of the effects of improving one or more of them and promoting the recovery of one or more of whole body endurance and endurance during aerobic exercise. In addition, one or more of reducing fatigue, promoting recovery from fatigue, and preventing fatigue, preferably deterioration of physical function resulting from continuous activities such as work and exercise. It is possible to bring about one or more actions of alleviating the decrease in physical function, promoting recovery of the decrease in physical function, and preventing the decrease in physical function to make the decrease in physical function less likely to occur. it can. Further, one or more of reducing the feeling of fatigue and reducing the sensation of being aware of the presence of fatigue, preferably discomfort and discomfort resulting from continued activities such as work and exercise. One or more actions of reducing / or reducing the decrease in activity motivation, promoting recovery of the discomfort and / or decrease in activity motivation, and preventing the discomfort and / or decrease in activity motivation. Can bring. Based on these actions, the composition of the present invention has an effect on nutritional supplementation in the case of nutritional tonicity, weak constitution, physical fatigue and the like.

<Proliferation composition of Bacteroides uniformis in the intestinal tract>
The present invention also relates to compositions for growing intestinal Bacteroides uniformis, including amani lignans. Subjects who received or received amanilignan had a significantly increased intestinal Bacteroides uniformis compared to before ingestion. Then, the subject who ingested or administered the amani lignan tends to improve the athletic ability. Therefore, it is considered that the increase in the number of Bacteroides uniforms in the intestinal tract by ingestion or administration of the composition of the present invention is one reason why the athletic ability can be improved.
Here, the intestinal flora (intestinal flora) is extremely complex and consists of an exquisite balance of bacterial composition, so even if a system capable of in vitro proliferation of Bacteroides uniformis alone is established, it is not possible. Can not be simply applied to Bacteroides unformis in the intestinal flora. It has been confirmed that the composition according to the present invention can actually significantly increase the number of Bacteroides uniformis in the intestinal tract of a mammal when ingested or administered into the body of a mammal.

The "Bacteroides uniformis" in the present invention is known, and the Bargies Manual of Bacteriology Vol. It can be characterized based on the known mycological properties described in 4 (1989) and the like. Bacteroides uniformis is an anaerobic gram-negative bacillus having a size of about 0.8 × 1.5 μm, which does not form spores and has no motility. Bacteroides uniformis is a eubacteria that is normally present in the intestines of many mammals, including humans.
The "Bacteroides uniformis" that can be propagated in the present invention are mammals (eg, humans, monkeys, chimpanzees, cows, horses, pigs, sheep, dogs, cats, mice, rats, etc.), preferably strains in the human intestine. is there.

The composition of the present invention can increase any strain classified as Bacteroides unformis. The Bacteroides uniformis to be increased may be a Bacteroides uniformis strain existing in the intestinal tract of the ingestion target of the composition of the present invention, or a Bacteroides uniformis strain ingested from the outside by the intake target. The Bacteroides uniformis strain to be ingested from the outside is not particularly limited as long as it is a Bacteroides uniformis strain, and examples thereof include ATCC8942 strain, CCUG4942 strain, CIP103695 strain, DSM6597 strain, NCTC13054 strain, JCM5828 strain, CP3585 strain and CP3586 strain. Be done. Preferably, it is JCM5828 strain, CP3585 strain and CP3586 strain. The JCM5828 strain is a reference strain registered and preserved in the Japan Collection of Microorganisms, BioResource Center, RIKEN (3-1-1, Koyadai, Tsukuba City, Ibaraki Prefecture, 305-0074). The CP3585 and CP3586 strains were sent to the Patent Microorganisms Depositary Center (Room 2-5-8122, Kazusakamatari, Kisarazu City, Chiba Prefecture, 292-0818) on August 25, 2017. It has been deposited internationally as 02536 and NITEBP-02537.

Bacteroides uniformis in the intestinal tract can be isolated and confirmed according to a known method (PaolaGaufinCanoetal, PLoSone.July2012, Volume7, Issue7, e41079). That is, mammalian feces, feces, and feces are diluted in an appropriate solvent, seeded on a plate medium, cultured under anaerobic conditions, and caught from colonies appearing on the medium. As the medium, those described in detail below can be used, but it is preferable to use a selective separation medium capable of distinguishing and selecting Bacteroides from the viewpoint of isolation efficiency (Jap. J. vet. Sci., 36, 93-98 (1974)). After confirming that the obtained bacteria are Gram-negative bacilli by Gram stain and microscopic examination, the selected bacteria are identified and cloned by analyzing the selected bacteria based on the nucleotide sequence of the 16S rRNA gene to identify and clone Bacteroides uniforms. be able to. The nucleotide sequence of the 16S rRNA gene of Bacteroides uniform is known, for example, it is disclosed in a known database such as GenBank, and is registered as NR_040866, AB050110, AB510711, L16486. These sequence information can be used in the analysis of the 16S rRNA gene. The analysis and identification of 16S rRNA genes are performed based on known methods such as quantitative PCR method, DGGE / TGGE method, FISH method, 16S rDNA cloning library method, T-RFLP method, FISH-FCM method, and nucleotide sequence determination method. Can be (Biochemistry, Vol. 80, No. 5, 421-425.2008; JNtr. 2004Feb; 134 (2): 465-72 .; Appl. Environ. Microbiol. 64.3336-3345.198; Appl. Environ. Microbiol., 65, 4799-4807, 1999; Appl. Environ. Microbiol., 62, 2273-2278, 1996; Appl. Environ. Microbiol., 64, 3854-3859, 1998).

For example, according to the quantitative PCR method, a primer specific to the bacterium is prepared based on the known nucleotide sequence information of the 16S rRNA gene of Bacteroides uniformis. Using the DNA extracted from the selected bacterium as a template, a PCR reaction is performed using the primer to determine whether or not the bacterium is Bacteroides uniformis based on the presence or absence of a PCR amplification product of the intended size. be able to. The design of specific primers and the determination of PCR conditions can be performed according to a standard method (Bio-Experimental Illustrated 3 Really Increased PCR: Cell Engineering Lab Notebook Series Seen in Attachment; Hiroki Nakayama, Shujunsha Co., Ltd.).

<Arbitrary additive>
The composition of the present invention can include, together with amani lignans, additives such as excipients, lubricants, binders, disintegrants, etc., which are commonly used in the manufacture of pharmaceuticals and foods and drinks, and are contemplated. It can be produced as a dosage form or form suitable for the administration route and ingestion method.

Excipients include lactose, sucrose, D-mannitol, D-sorbitol, starch, pregelatinized starch, dextrin, cyclodextrin, glucose, corn starch, crystalline cellulose, low substitution hydroxypropyl cellulose, sodium carboxymethyl cellulose, gum arabic, Examples thereof include pullulan, light anhydrous silicate, synthetic aluminum silicate, and magnesium aluminometasilicate.

Examples of the lubricant include sugar esters such as sucrose fatty acid ester and glycerin fatty acid ester, hydrogenated oils such as calcium stearate, magnesium stearate, stearic acid, stearyl alcohol, powdered vegetable oils and fats, and waxes such as sala shimitsuro. Examples include talc, silicic acid, silicon and the like.

Binders include pregelatinized starch, sucrose, gelatin, gum arabic, methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, purulan, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl. Pyrrolidone and the like can be mentioned.

As the disintegrant, lactose, sucrose, starch, carboxymethyl cellulose, filtration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization and the like are appropriately used. It can be selected and used in combination.

Further, as an example of the additives usually used in the production of pharmaceuticals and foods and drinks that can be used in the composition of the present invention, various fats and oils (for example, vegetable oils such as soybean oil, corn oil, saflower oil and olive oil) are used. , Beef fat, animal fats and oils such as sardine oil), crude drugs (eg royal jelly, carrots, etc.), amino acids (eg glutamine, cysteine, leucine, arginine, etc.), polyhydric alcohols (eg ethylene glycol, polyethylene glycol, propylene glycol, glycerin, Sugar alcohols, such as sorbitol, erythritol, xylitol, martitol, mannitol, etc., natural polymers (eg, arabic gum, agar, water-soluble corn fiber, gelatin, xanthan gum, casein, gluten or gluten hydrolyzate, lecithin, starch, Dextrin, etc.), vitamins (eg, vitamin C, vitamin B group, etc.), minerals (eg, calcium, magnesium, zinc, iron, etc.), dietary fiber (eg, mannitol, pectin, hemicellulose, etc.), surfactants (eg, glycerin fatty acid ester, etc.) Sorbitol fatty acid ester, etc.), purified water, molding aid (tricalcium phosphate, etc.), fluidity improver (tricalcium phosphate, etc.), diluent, stabilizer, tonicity agent, pH adjuster, buffer , Wetting agents, solubilizing agents, suspending agents, coloring agents, flavoring agents, flavoring agents, fragrances, antioxidants, sweeteners, taste components, acidulants and the like.

<Any other active ingredient>
In addition to the active ingredient amani lignan, the composition of the present invention can include other ingredients known to have one or more of a physical fitness improving effect, an anti-fatigue effect, and a feeling of fatigue reduction. Other such ingredients include taurine, glutathion, carnitine, creatine, coenzyme Q10, glucuronic acid, glucuronolactone, galana extract, theanine, gamma-aminobutyric acid (GABA), capsaicin, capsiate, alicin, vitamins (vitamins). B1, B2, B6, B12, C, E, etc.), various organic acids (citrate, etc.), flavonoids, polyphenols, catechins, caffeine, etc., but are not limited thereto.
Further, it is more preferable that the composition of the present invention contains α-cyclodextrin as an active ingredient in addition to amani lignan. The mass ratio of amanilignan: α-cyclodextrin in the composition is 1: 0.1 to 3, more preferably 1: 0.3 to 2, and more preferably 1: 0.6 to 1.5.

Further, although the composition of the present invention is used for growing Bacteroides uniformis, the composition may contain Bacteroides uniformis or a processed product thereof as another active ingredient. The Bacteroides uniformis that can be used in the present invention can be cultured and recovered using a normal culture medium and culture conditions in which the bacterium can be cultured.

The culture medium may be any as long as it can cultivate Bacteroides unformis, and is not particularly limited. For example, as a carbon source, glucose, fructose, galactose, maltose, lactose, cellobiose, sucrose, lambnorse, amigdarin, esculin, salicin are used. , Meribiose, trehalose, L-arabinose, ribose, D-xylose, inulin, raffinose, starch, sugar honey, etc., inorganic ammonium salts such as zinc sulfate, magnesium sulfate, urea, amino acids, meat extract, yeast extract, polypeptone, protein as nitrogen sources Organic nitrogen-containing substances such as decomposition products and inorganic salts can include magnesium sulfate, potassium dihydrogen phosphate, potassium tartrate, zinc sulfate, magnesium sulfate, copper sulfate, calcium chloride, iron chloride, manganese chloride and the like. .. A known culture medium suitable for culturing Bacteroides unformis (for example, NBGT medium, BL medium, GAM medium, etc.) can be used. The culture medium is preferably a liquid medium, but if necessary, agar or gelatin may be added and used as a solid medium or a semi-fluid medium. The culture can be carried out at a temperature of 20 ° C. to 50 ° C., preferably 25 ° C. to 45 ° C., more preferably 35 ° C. to 37 ° C. under anaerobic conditions. The "anaerobic condition" may be any hypoxic environment to the extent that Bacteroides unformis can proliferate. For example, an anaerobic chamber, an anaerobic box, a closed container containing an oxygen scavenger, a culture container, or the like is used. Can be.

The culture can be performed in any form such as static culture, shaking culture, tank culture, etc., and the culture time is not particularly limited, but can be, for example, 3 hours to 7 days.

After culturing, the obtained culture may be used as it is, or Bacteroides unformis may be purified or crudely purified from the culture before use.

Purification or crude purification of the cells from the culture can be performed by any means, for example, centrifugation, filtration or the like.

The Bacteroides uniformis used in the present invention may be a wet cell or a dry cell.

In the present invention, a processed product of Bacteroides unformis can also be used. In the present invention, examples of the "processed product" include a bacterial cell complex of Bacteroides unformis. The bacterial cell complex can be obtained by coding Bacteroides uniformis with a coating agent, and can be obtained by a known treatment. Examples of the coating agent include polysaccharides such as starch, amylose, cellulose, hemilose, mannan, and chitosan, and thickening polysaccharides such as gelatin, gellan gum, locust bean gum, carrageenan, farceleran, tamarind, and pectin, casein, and the like. And proteins such as non-fat dry milk.

The Bacteroides uniformis or its processed product used in the present invention can be used in any form such as a dried product, a frozen product, an aqueous dispersion, and an emulsion. The dried product can be obtained by using any drying means such as spray drying, drum drying, vacuum drying, freeze drying, etc., and can be in the form of powder or granules.

<Aspect of composition>
The dosage form or form of the composition of the present invention is not particularly limited. As the pharmaceutical, for example, tablets, capsules, granules, powders, powders, syrups, dry syrups, liquids, suspensions, inhalants, suppositories and the like can be used, but oral preparations are preferable. Is. Liquid preparations such as liquid preparations and suspensions are provided in a state where they can be freeze-dried and stored, and are used after being dissolved in a buffer solution containing water or a saline solution, etc. to prepare an appropriate concentration before use. It may be what is done. Further, those having a solid dosage form such as tablets may be coated if necessary (for example, sugar-coated tablets, gelatin-encapsulated tablets, enteric-coated tablets, etc.), and using known techniques, The release may be controlled, such as a sustained release formulation, a delayed release formulation or an immediate release formulation.

Foods and drinks include, for example, healthy foods and drinks in the form of tablets, tablets, chewable tablets, powders, powders, capsules, granules, drinks, etc. (supplements, nutritional supplements, health supplements, nutritionally adjusted foods, etc.) , Soft drinks, tea drinks, jelly drinks, sports drinks, coffee drinks, carbonated drinks, vegetable drinks, fruit juice drinks, fermented vegetable drinks, fermented fruit juice drinks, fermented milk drinks (yogurt, etc.), lactic acid bacteria drinks, milk drinks, powder drinks, It can be in the form of cocoa beverages, confectionery (eg, biscuits and cookies, chocolate, candy, chewing gum, tablets), jelly and the like (but not limited to these).

Foods and drinks include health functional foods (foods for specified health use (including conditional specified health foods), foods with nutritional function, foods with functional claims, health foods, beauty foods, etc.) containing ingredients that improve athletic performance. Can be.

Further, the composition of the present invention can be in the form of feed or feed additive for livestock, racehorses, pets, etc., as well as food and drink for humans.

The following examples are merely examples of the subjects disclosed herein and should never be considered as limiting the scope of the disclosed subjects.

1. 1. Subjects and selection criteria Twenty-one healthy men aged 20 to 49 years who have an exercise habit of exercising at an intensity of 5 METs or more for 30 minutes or more once or twice a week and who can continue the exercise habit during the test period were selected as subjects. ..
Of the 21 patients, 10 were in the amanilignan intake group and the remaining 11 were in the placebo group. The subjects themselves did not know which group they belonged to.
2. Test food A test food (tablet) having the composition shown in Table 1 below was used. One grain of the test food was about 250 mg. As the amani lignan powder, Nippon Amani lignan (Nippon Flour Mills Co., Ltd.) was used. Nippon Amani lignans contain 40% by mass or more of SDG and cyclodextrin as other components.

3. 3. Test period and evaluation items Three tablets of the above test food were ingested once a day by each subject in the amanilignan intake group and the placebo group at any time. That is, the subjects in the amani lignan intake group were asked to ingest about 200 mg of Nippon Amani lignan (at least about 80 mg of SDG per day).
The intake period of the test food was 9 weeks, and changes in the intestinal flora were evaluated before the start of intake, 4 weeks after intake, and 8 weeks after intake, and a fatigue questionnaire was conducted before the start of intake and 9 weeks after intake. Maximum oxygen intake was later assessed. During the test period, they lived the same as before the test. In addition, foods and beverages that claim to support sports and training, medicines and quasi-drugs whose effects include recovery, prevention, and improvement of "fatigue,""tiredness,""physicalstrength," and / or "dullness." , And general supplements (including foods with functional claims and foods for specified health use) were designated as foods prohibited from intake for one week from the date of consent to participate in the test and during the test period.

[Example 1] Intestinal Bacteroides / Uniformis Proliferation Effect Test with Amani Lignan Changes in the intestinal Bacteroides / Uniformis of the subjects were confirmed. Feces were collected from each subject before, 4 weeks, and 8 weeks after ingestion of the test food and used for evaluation.
DNA was extracted from the collected feces by a conventional method, and a specific sequence in the 16S rDNA sequence region of Bacteroides uniformis was targeted with reference to the description of Anaerobe (2011), 17, 64-68, and Jia Tong et al. Quantitative PCR (probe method) was performed by a conventional method using the above-mentioned forward primer, reverse primer, and probe to evaluate the absolute number of Bacteroides unformis in the intestinal tract.
Forward primer sequence: 5'-TCTTCCGGCATGGTAGAACTATA-3'(SEQ ID NO: 1)
Reverse primer sequence: 5'-ACCGTGTCTCAGTTCCAATGTG-3'(SEQ ID NO: 2)
Probe sequence: 5'-CGTTCCATTTAGGTTGTGCGCGGG-3'(SEQ ID NO: 3)
The results are shown in FIG. In the amanilignan intake group, the absolute number of Bacteroides uniformis in the intestinal tract increased about four times after 8 weeks (8w) of intake as compared with before intake (0w). On the other hand, in the placebo group, no statistically significant change was observed in the number of Bacteroides uniformis in comparison between before and 8 weeks after ingestion. The statistical examination of the number of bacteria before and 8 weeks after ingestion was performed by Wilcoxon signed-rank test (*: p <0.05).

[Example 2] Exercise reduction test using amani lignans Exercise bike (registered trademark) (manufactured by Konami Sports & Life Co., Ltd., model number AEROBIKE-) for subjects before, 4 weeks, and 8 weeks after ingestion of the test food. Exercise load (load intensity: 45% of the maximum exercise load intensity for each subject for 50 minutes) was performed by 75XLIII). In this embodiment, the maximum exercise load intensity refers to the weight (W) of the pedal immediately before exhaustion in the gradual increase load test in which the exercise load intensity is increased by 15 w per minute, which is performed in advance. Regarding fatigue immediately after loading, 30 minutes after loading, and 60 minutes after loading, a VAS (Visual Analogue Scale) questionnaire was conducted based on the fatigue feeling VAS inspection method established by the Japan Fatigue Society to investigate changes in fatigue feeling over time. .. The item of the questionnaire was "whole body fatigue", and "0 mm" was evaluated as "best condition" and "100 mm" was evaluated as "worst condition". In addition, after explaining to the subject that the "best condition" is the best sensation without feeling tired at all, and the "worst condition" is the worst sensation that is so exhausted that nothing can be done, the subject is evaluated. It was. When the measured values 8 weeks after ingestion of each intake group were evaluated, the general fatigue feeling after 30 minutes of exercise load was significantly reduced (that is, the fatigue feeling was reduced) in the amani lignan intake group as compared with the placebo group. It was. In addition, it was suggested that in the amani lignan intake group, fatigue tolerance was also improved as compared with before intake, especially after 8 weeks of intake. The comparison was performed by a student's t-test, and the results are summarized in a graph in FIG. 2 (*: p <0.05).

[Example 3] Physical fitness (whole body endurance) improvement test by amani lignan (maximum oxygen uptake)
Exercise load by exercise bike (registered trademark) (Konami Sports & Life Co., Ltd., model number AEROBIKE-75XLIII) before and 9 weeks after ingestion of the test food in order to evaluate the change in whole body endurance due to ingestion of amani lignan. I had an exam taken. The test was conducted until exhaustion under the condition that the load was increased by 15 W per minute while maintaining the pedal rotation speed at 60 rpm. When the maximum oxygen uptake (VO ₂ max) was measured using an aero monitor during exercise (manufactured by Minato Medical Science Co., Ltd., model number AE-310s), the maximum oxygen uptake was 0 weeks in the amanilignan intake group. In comparison, it increased 9 weeks after ingestion. A significant difference was examined by paired t-test for comparison of maximal oxygen uptake before and 9 weeks after ingestion of amanilignan. The results are shown in FIG. 3 (p = 0.06).
From the results of FIG. 3, it was found that the intake of amani lignan not only reduces the feeling of fatigue but also contributes to the improvement of physical fitness, especially the endurance of the whole body and the endurance during aerobic exercise. In addition, the results shown in FIG. 3 indicate that ingestion of amani lignan also contributes to improvement of fatigue tolerance.
The data from Examples 1 to 3 supported that intake of amani lignans contributed to the improvement of athletic performance.

Claims

A composition for improving athletic performance containing amani lignan as an active ingredient.
The composition according to claim 1, wherein the improvement of athletic ability includes at least one action selected from improvement of physical strength, anti-fatigue, and reduction of fatigue.
A composition for breeding Bacteroides uniformis in the intestinal tract containing amani lignan as an active ingredient.
The composition according to any one of claims 1 to 3, which is for oral ingestion.
The composition according to any one of claims 1 to 3, which is an additive for food and drink, a pharmaceutical composition, a feed composition, or an additive for feed.
The composition according to any one of claims 1 to 5, wherein an amani lignan in an amount of 0.01 mg mg / kg body weight to 200 mg / kg body weight is administered per day.
The composition according to any one of claims 1 to 6, which is administered for at least 7 days.